Gilead Sciences Inc. (GILD, Financial), CVS Health Corp. (CVS, Financial), Walgreens Boots Alliance Inc. (WBA, Financial) and Vodafone Group PLC (VOD, Financial) have declined to their three-year lows.
Gilead Sciences declined to $63.23
The price of Gilead Sciences Inc. (GILD, Financial) shares declined to $63.23 on March 8, which is 4.6% above the three-year low of $60.32.
Gilead Sciences is an American international pharmaceutical and biotechnology company that develops and commercializes therapeutics. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C and influenza. Some of the products the company developed include AmBisome, Atripla, Cayston, Emtriva and Flolan.
The company has a market cap of $80.65 billion; its shares were traded around $63.23 with a price-earnings ratio of 15.17 and a price-sales ratio of 3.73. The trailing 12-month dividend yield is 3.61%. The forward dividend yield is 4.03%. Gilead Sciences had an annual average earnings growth of 26.20% over the past 10 years.
On March 7, the company announced data from two studies supporting the further development of GS-6207, a novel selective inhibitor of HIV-1 caspid function. The drug could potentially be used as part of a long-acting HIV combination therapy. Phase 1 results demonstrated that single doses of the drug achieved sustained concentration levels and were well tolerated, while in vitro data demonstrated the efficacy of the drug against HIV strains resistant to other antiretroviral classes.
CVS Health declined to $52.93
The price of CVS Health Corp. (CVS, Financial) shares declined to $52.93 on March 8, which is 1.6% above the three-year low of $52.10.
CVS Health is an American retail pharmacy and health care company. The business began as a chain of health and beauty stores, but later added pharmacies. The company owns several subsidiaries, including CVS Pharmacy, MinuteClinic, Caremark Rx, Longs Drugs, Omnicare and Navarro Discount Pharmacies.
The company has a market cap of $68.65 billion; its shares were traded around $52.93 with a price-sales ratio of 0.28. The trailing 12-month dividend yield is 3.79%. The forward dividend yield is 3.82%. CVS had an annual average earnings growth of 7.40% over the past decade.
On Feb. 20, CVS reported financial results for fourth-quarter and full-year 2018. Revenue for the quarter increased 12.5% to $54.4 billion. The GAAP diluted loss per share was 37 cents, including a $2.2 billion goodwill impairment charge. Adjusted earnings were $2.14 per share for the quarter. The company also completed its $70 billion acquisition of Aetna.
Walgreens Boots Alliance declined to $59.90
The price of Walgreens Boots Alliance shares declined to $59.90 on March 8, which is 1.4% above the three-year low of $59.07.
Walgreens Boots Alliance is an American holding company that owns Walgreens, Boots and other pharmaceutical manufacturing, wholesale and distribution companies.
The company has a market cap of $56.51 billion; its shares were traded around $59.90 with a price-earnings ratio of 11.03 and a price-sales ratio of 0.44. The trailing 12-month dividend yield is 2.87%. The forward dividend yield is 2.94%. Walgreens had an annual average earnings growth of 5.90% over the past 10 years.
On Jan. 25, Walgreens announced its board of directors declared a regular quarterly dividend of 44 cents per share, unchanged from the previous quarter. The dividend will be payable on March 12 to shareholders of record at the close of business on Feb. 15.
Vodafone declined to $17.83
The price of Vodafone shares declined to $17.83 on March 8, which is 4.4% above the three-year low of $17.05.
Vodafone is a British international telecommunications conglomerate that is ranked fourth in the world by the number of mobile customers as of 2018. The company owns and operates networks in 25 countries and has partner networks in 47 other countries.
The company has a market cap of $49.45 billion; its shares were traded around $17.83 with a price-sales ratio of 0.93. The trailing 12-month dividend yield is 9.75%. The forward dividend yield is 6.17%. Vodafone had an annual average earnings growth of 28.50% over the past five years.
On Feb. 20, Vodafone announced it became the world’s first operator to connect 5G smartphones to its live 5G network. The company successfully completed trials over a four-week period with three 5G smartphones that will be launched in 2019 and is preparing to launch 5G in various European cities during the second half of the year.
Disclosure: I do not own shares of any of the companies mentioned in the article.
